haygx,
You better put me on ignore I was a holder & sold - therefore my opinion means nothing.
Hugh Alsop former role include director of Business Development for Acrux where his highlight achievement was his role in the Axiron licensing to Eli Lilly in March 2010 (He was there approx 6 years)
Prior to that responsible for expanding Sigma Pharmaceuticals export market to Europe (many years)
Hugh Alsop was also appointed VP of Phosphagenics in March 2012 resigned in March 2013 - hmmmm only one year
Strangely there was minimal mention here & quickly fobbed off, because he moved to be the CEO of Hatchtech (head lice treatment)
my thoughts were what vision did he see or not see?
three months on...., page-20
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(20.0%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $2 | 1.126K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 34751789 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 40153304 | 27 |
View Market Depth
| Last trade - 12.40pm 08/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |